Transparency Document
NCCN Guidelines for Anal Carcinoma V.1.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 4176 |
ANAL-B 2 of 3
Repotrectinib Submission from BMS on 06-14-2024 |
Add repotrectinib as a preferred Category 2A recommended first-line targeted treatment option for patients with NTRK-positive locally advanced or metastatic anal carcinoma Add repotrectinib as a preferred Category 2A recommended subsequent-line treatment option for patients with NTRK-positive locally advanced or metastatic anal carcinoma whose disease progressed on a prior NTRK targeted treatment |
Change not made |
Yes: 0 No: 30 Abstain:0 Absent:4 |
|
| 4756 - Internal Request | ANAL-3, ANAL-4, ANAL-B 2 of 5, ANAL-B 3 of 5 | Comment to include checkpoint inhibitor immunotherapy/FDA-approved PD-1 inhibitors (cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, toripalimab-tpzi) as second-line/subsequent therapy treatment options for metastatic disease or as immunotherapy options for local recurrence before proceeding to APR | Change made |
Yes: 30 No: 0 Abstain:0 Absent:4 |